Neosol 70% Infusion — Dextrose 70% by Beximco Pharmaceuticals

Neosol 70% Infusion — Dextrose 70% | Beximco Pharmaceuticals

Overview

Neosol 70% is a concentrated Dextrose (Glucose) 70% w/v solution for intravenous use. As a highly concentrated solution, it must always be diluted to an appropriate concentration before administration — typically to 5–50% dextrose depending on the clinical indication and route of administration. Dextrose 70% is primarily used as a component of Total Parenteral Nutrition (TPN) formulations, as a concentrated caloric source in fluid-restricted patients, and for rapid correction of severe hypoglycaemia in hospital settings. It provides 2.38 kcal per mL as a 70% solution (before dilution).

Clinical Uses

• Total Parenteral Nutrition (TPN): Central component of hospital TPN bags — diluted with amino acids, lipids, electrolytes, and micronutrients
• Severe hypoglycaemia: Diluted to 25–50% and given as IV bolus for reversal of severe or unconscious hypoglycaemia when oral/buccal glucose is not possible
• Caloric supplementation: In patients unable to tolerate enteral nutrition — provides concentrated glucose calories in minimal volume
• Hyperkalaemia management: Component of glucose-insulin IV infusion to drive potassium intracellularly

Critical Diabetic Patient Warnings

• HYPERTONIC SOLUTION — NEVER give undiluted into a peripheral vein: Dextrose 70% is highly hypertonic and causes severe thrombophlebitis, vein damage, and tissue necrosis if given peripherally undiluted. It must be administered via a central venous catheter or diluted to ≤10% for peripheral infusion.
• Rebound hyperglycaemia: IV dextrose, even when given for hypoglycaemia reversal, causes rapid blood glucose elevation. Monitor blood glucose every 15–30 minutes after administration and adjust as needed.
• Hyperosmolar state: Concentrated dextrose infusions in diabetic patients with impaired insulin response can precipitate hyperosmolar hyperglycaemic state (HHS) — use minimum effective dose and monitor closely.
• Insulin co-administration: In TPN, insulin is added to the bag or given separately to maintain normoglycaemia — target glucose 6–10 mmol/L in ICU patients.
• Thiamine before glucose in unknown cases: In malnourished or alcohol-use patients presenting with altered consciousness, give IV thiamine BEFORE dextrose to prevent precipitating Wernicke's encephalopathy.

Preparation and Administration

Side Effects and Complications

Hyperglycaemia, fluid overload, electrolyte disturbances (dilutional hyponatraemia, hypokalaemia with insulin-mediated K⁺ shift). Thrombophlebitis if peripheral vein used without adequate dilution. Hyperchloraemia if mixed with saline. Refeeding syndrome in severely malnourished patients — introduce gradually.

Storage

Store at controlled room temperature 15–25°C. Protect from freezing and excessive heat. Do not use if solution is discoloured or contains visible particles. Single use only after dilution.

Medical Disclaimer: Dextrose 70% is a concentrated hospital-use product requiring dilution before administration. It must only be used by trained healthcare professionals in clinical settings. Diabetic patients must have blood glucose monitored closely during and after administration. Not for home use. Prescription required.